Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interaction between FK 506 and clarithromycin in a renal transplant patient.

Literature DB >> 7532134

Interaction between FK 506 and clarithromycin in a renal transplant patient.

K Wolter, K Wagner, T Philipp, E Fritschka.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Clarithromycin
Tacrolimus

Year: 1994 PMID： 7532134 DOI： 10.1007/bf00194974

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

6 in total

1. Pharmacokinetics of FK 506 in transplant patients.

Authors: R Venkataramanan; A Jain; V S Warty; K Abu-Elmagd; M Alessiani; J Lever; A Krajak; J Flowers; S Mehta; S Zuckerman
Journal: Transplant Proc Date: 1991-12 Impact factor: 1.066

2. FK 506 interaction with danazol.

Authors: R Shapiro; R Venkataramanan; V S Warty; V P Scantlebury; W Rybka; J McCauley; J J Fung; T E Starzl
Journal: Lancet Date: 1993-05-22 Impact factor: 79.321

3. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism.

Authors: S H Vincent; B V Karanam; S K Painter; S H Chiu
Journal: Arch Biochem Biophys Date: 1992-05-01 Impact factor: 4.013

Review 4. Pharmacokinetic drug interactions of macrolides.

Authors: P Periti; T Mazzei; E Mini; A Novelli
Journal: Clin Pharmacokinet Date: 1992-08 Impact factor: 6.447

5. Clarithromycin-carbamazepine interaction: a case report.

Authors: F Albani; R Riva; A Baruzzi
Journal: Epilepsia Date: 1993 Jan-Feb Impact factor: 5.864

6. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors: K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1988-10 Impact factor: 5.191

6 in total

10 in total

1. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Authors: Sara K Quinney; Srikar R Malireddy; Raj Vuppalanchi; Mitchell A Hamman; Naga Chalasani; J Christopher Gorski; Stephen D Hall
Journal: Eur J Clin Pharmacol Date: 2012-07-10 Impact factor: 2.953

Review 2. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors: H D Langtry; R N Brogden
Journal: Drugs Date: 1997-06 Impact factor: 9.546

Interaction between FK 506 and clarithromycin in a renal transplant patient.

1. Pharmacokinetics of FK 506 in transplant patients.

2. FK 506 interaction with danazol.

3. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism.

Review 4. Pharmacokinetic drug interactions of macrolides.

5. Clarithromycin-carbamazepine interaction: a case report.

6. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

1. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Review 2. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Review 3. Clinical pharmacokinetics of clarithromycin.

Review 4. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Review 5. Clinically significant drug interactions with new immunosuppressive agents.

6. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

Review 7. Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Review 8. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

9. Tacrolimus toxicity in islet transplantation due to interaction with macrolides.

10. Outcomes Following Macrolide Use in Kidney Transplant Recipients.